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AbsTrACT
Objectives To examine the influence of the 
glucocerebrosidase (GBA) mutation carrier state on 
age at onset of parkinson’s disease (pD), the motor 
phenotype and cognitive function at baseline assessment 
in a large cohort of UK patients. We also analysed the 
prevalence of mood and behavioural problems that may 
confound the assessment of cognitive function.
Methods We prospectively recruited patients with pD 
in the Tracking Parkinson’s study. We fully sequenced 
the GBA gene in all recently diagnosed patients (≤3.5 
years). We examined cognitive (Montreal cognitive 
assessment) and motor (Movement Disorder society 
Unified parkinson’s Disease Rating scale part 3) function 
at a baseline assessment, at an average of 1.3 years 
after diagnosis. We used logistic regression to determine 
predictors of pD with mild cognitive impairment and pD 
with dementia.
results We studied 1893 patients with pD: 48 (2.5%) 
were heterozygous carriers for known Gaucher’s disease 
(GD) causing pathogenic mutations; 117 (6.2%) had 
non-synonymous variants, previously associated with 
pD, and 28 (1.5%) patients carried variants of unknown 
significance in the GBA gene. L444p was the most 
common pathogenic GBA mutation. patients with 
pathogenic GBA mutations were on average 5 years 
younger at disease onset compared with non-carriers 
(p=0.02). pD patients with GD-causing mutations did 
not have an increased family risk of pD. patients with 
GBA mutations were more likely to present with the 
postural instability gait difficulty phenotype compared 
with non-carriers (p=0.02). patients carrying pathogenic 
mutations in GBA had more advanced hoehn and Yahr 
stage after adjustment for age and disease duration 
compared with non-carriers (p=0.005). There were no 
differences in cognitive function between GBA mutation 
carriers and non-carriers at this early disease stage.
Conclusions Our study confirms the influence of GBA 
mutations on the age of onset, disease severity and 
motor phenotype in patients with pD. cognition did 
not differ between GBA mutation carriers and non-
carriers at baseline, implying that cognitive impairment/
dementia, reported in other studies at a later disease 
stage, is not present in recently diagnosed cases. This 
offers an important window of opportunity for potential 
disease-modifying therapy that may protect against the 
development of dementia in GBA-pD.
Clinical trial registration NcT02881099; Results. 
InTrOduCTIOn
Initial reports of an association between some types 
of Gaucher’s disease (GD) and parkinsonism led 
to the investigation of the link between heterozy-
gous mutations in the gene coding for the enzyme 
glucocerebrosidase (GBA) and Parkinson’s disease 
(PD).1 2 GBA mutations are common in PD and 
are the most important risk factor yet discovered 
for PD.3 A multicentre study of GBA mutation 
carriers, spanning three continents, established that 
the OR for any GBA mutation in patients with PD 
versus controls without PD was about 5.4.4 Vari-
ants in GBA can influence the phenotype of PD.5 
Mutations that are not commonly recognised as 
causing GD have been found in patients diagnosed 
with PD6 and in particular the GBA E326K variant 
may predispose to PD.7 As compared with patients 
who do not carry a GBA mutation, those with GBA 
mutations have been reported to present earlier, 
are more likely to have affected relatives and are 
more likely to have atypical clinical manifestations.4 
Furthermore, mild and severe heterozygous GBA 
mutations can differentially affect the risk and the 
age at onset of PD.8 GBA mutation carriers with 
PD are on a trajectory to cognitive decline9 despite 
clinicopathological studies showing no statistically 
significant difference in Braak stages between GBA 
mutation carriers and sporadic PD controls.10 
Motor progression rates differ in GBA mutation 
carriers with PD. The HR for progression to Hoehn 
and Yahr stage 3 is significantly greater in GBA 
mutation carriers with PD compared with non-car-
riers.11 There is also evidence to suggest that carriers 
of polymorphisms in GBA which are not generally 
considered to increase PD risk are at significantly 
increased risk of progression to Hoehn and Yahr 
stage 3.11 More recent data from a prospective 
longitudinal study suggest that GBA-associated 
patients with PD not only have more rapid progres-
sion of disease but also have reduced survival.12
Cognitive impairment is a common problem 
in the later stages of PD,13 but even in early-stage 
disease there are mild deficits that can be identified 
on formal cognitive testing.14 Cognitive impairment 
in PD exists on a spectrum from mild cognitive 
impairment in PD (PD-MCI) to dementia (PD-D). 
Further, some types of PD-MCI may be a harbinger 
of dementia which occurs in up to 80% of patients 
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over 15–20 years.13 and recent studies have identified several 
genetic factors that influence this including ApoE, MAPT and 
SNCA.14 15 GBA mutation status is reported as an independent 
risk factor for cognitive impairment in patients with PD.16 17 
Further, GBA variants are reported to associate with a distinct 
pattern of cognitive deficits in PD characterised by greater 
impairment in working memory, executive function and visuo-
spatial abilities.18 The individual risk of dementia in PD patients 
with GBA mutations is increased sixfold in carriers compared 
with non-carriers.17 The HRs for progression both to dementia 
and Hoehn and Yahr stage 3 are significantly greater in GBA 
mutation carriers compared with non-carriers, and in fact muta-
tions in GBA have also been found in cases with dementia with 
Lewy bodies (DLB), thus pointing towards a link between GBA, 
parkinsonism and dementia.19
This collection of evidence from smaller studies linking GBA 
mutation status to several clinical phenotypic characteristics 
including disease progression and survival in PD has implications 
for genetic counselling, clinical follow-up and stratification in 
future clinical trials.
We assessed the influence of GBA mutations on the age of 
onset of PD, early motor phenotype, motor staging and cognitive 
function in a very large cohort of patients (n>2000, figure 1).
MeThOds
Tracking Parkinson’s is a large prospective, observational, multi-
centre project in the UK. The study set-up and design have been 
previously reported.20 Patients were recruited with a clinical 
diagnosis of PD, fulfilling Queen Square Brain Bank criteria21 and 
supported by structural and/or functional neuroimaging. Both 
drug-naive and treated patients aged 18–90 years were eligible. 
Recent onset cases were diagnosed with PD in the preceding 3.5 
years, and recruitment was completed between February 2012 
and May 2014. Patients with a clinical diagnosis of dementia 
at their first assessment were excluded. Enrolled patients whose 
diagnosis was later changed, on clinical or imaging grounds, 
were excluded from analysis. Additionally, patients with atyp-
ical features, which might indicate an alternative diagnosis, were 
excluded from the data analysis (figure 1).
Motor subtypes were determined from the Movement 
Disorder Society Unified Parkinson’s Disease Rating Scale part 
3 (MDS-UPDRS 3) scores using a predetermined formula.22 The 
Montreal Cognitive Assessment (MoCA) test scores were adjusted 
for years of education and predetermined diagnostic cut-offs were 
used, to categorise cases into normal (>23), MCI 22–23 and 
dementia (<22), matching previous similar studies.20 23 Depression 
Figure 1 patient recruitment and assessment in this study. The main analysis of cognitive function using the Montreal cognitive assessment was 
performed in cases without features that might be atypical for parkinson’s disease (pD). GBa, glucocerebrosidase psa, progressive supranuclear palsy, Msa, 
multiple system atrophy.
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and anxiety were identified from scores >6 in the Leeds Hospital 
Anxiety and Depression Scale.24 Rapid eye movement (REM) sleep 
behaviour disorder (RBD) was defined as a score >4 on the RBD 
screening questionnaire.20 Olfaction testing was performed using 
either the 40-item University of Pennsylvania Smell Identification 
Test or Sniffin’ Sticks 16-item version, and hyposmia was defined as 
previously reported.25
Molecular genetic analysis of GbA mutations
The coding exons of GBA were screened using a nested PCR 
protocol followed by DNA sequencing described by Neumann 
et al.10 In accordance with the established convention for 
GBA alleles, all genetic variants were named according to the 
processed protein excluding the 39 residue signal peptide. 
Genetic variants were classified according to the criteria 
suggested by Winder-Rhodes et al11; GBA mutations that had 
been previously identified as being pathogenic in GD and associ-
ated with PD in the heterozygous state (group 1: e.g. L444P and 
G370S), non-synonymous genetic variants that have been linked 
to GD when occurring with other GBA mutations and have 
been associated with PD (group 2: eg, E326K and T369M) and 
genetic variants of unknown significance (group 3). Cases were 
then classified into one of these three groups depending on their 
GBA mutation status. Individuals with no sequence variants were 
classed as ‘non-carriers’ and combined with individuals from 
group 3. Further, analyses were performed comparing groups 1 
and 2 with non-carriers of GBA mutations (group 3). Subgroup 
analyses were subsequently performed to compare cognition in 
p.L444P carriers to non-carriers and p.L444P mutation carriers 
to p.N370S carriers. Additional analyses were also performed to 
compare cognition in those with atypical features who carried 
GBA mutations and non-carriers.
statistical analyses
Demographic and phenotypic characteristics were analysed 
using multivariable regression. Analyses of continuous vari-
ables (where UPDRS 3 and  Parkinson's disease questionnaire 
8 items (PDQ8) scores were assumed continuous) were carried 
out using linear regression and binary variables using logistic 
regression. For MoCA scores, standard linear regression was 
used; for individual MoCA domains, ordered logistic regres-
sion was used. Where a category had small numbers (<3% of 
total), it was merged with the category above to ensure stability. 
Comparisons of Hoehn and Yahr stages were also carried out 
with ordered logistic regression. Comparisons of motor subtypes 
were performed using multinomial logistic regression with 
tremor dominant group as the comparator.
All P values were two-tailed; P values were calculated after adjust-
ment for potential confounders where the confounders are listed 
in each table. The linearity of continuous confounders (such as age 
and disease duration) was tested using fractional polynomials in 
univariate models and then transformed if they showed evidence 
of non-linearity. We tested the proportional odds assumption in all 
ordered logistic regression models (except supplementary subgroup 
analyses with smaller numbers). All of these passed except within 
three models, and relaxing the model to a non-proportional odds 
model made no qualitative difference to the results.
Finally, we performed additional imputed analyses due to 
some missing data in the years of education (n=107), in the full 
MoCA test questionnaire (n=140) and within individual MoCA 
domains (varying between n=22–67 missing data elements). 
This involved using the chained equation approach to multiple 
imputation, creating 10 imputed datasets, then deriving esti-
mates and P values with Rubin’s rules.
Statistical analyses were performed using STATA 
V. 13 (StataCorp).
resulTs
A total of 5 different pathogenic mutations, 28 variants of unknown 
significance (including two exon deletions) and 2 PD-associated 
non-GD variants (E326K, T369M) were found among 1893 
patients with PD. Of these 1893 cases, 48 (2.5%) carried one or 
more GD pathogenic mutations; all of these cases were simple 
heterozygotes. In total, 117 carried PD-associated variants: 86 
(4.5%) carried E326K mutation(s) (one case was homozygous for 
this mutation; the rest were heterozygous), 35 (1.8%) carried the 
T369M mutation (table 1) and 1728 were non-carriers of GBA 
mutations. Four carried more than one PD-associated variant. 
There were 167 cases with atypical features: 144 (86.2%) were 
non-carriers but 23 (13.8%) tested positive for GBA mutations. Of 
these 23 cases, 4 (2.4%) showed GD pathogenic variants while 19 
(11.4%) had PD-associated non-GD variants (E326K or T369M). 
Detailed comparisons of phenotypic characteristics (tables 2–4) 
were performed on those without atypical clinical features that 
could raise suspicion of an alternative diagnosis (n=1726) (figure 1).
demographic and clinical features
In 142 PD cases who had a variant detected in the GBA gene (all 
cases), mean age was 65.6 years (SD 10.1) years, mean disease 
duration was 1.3 (SD 0.9) years and 93 (65.5 %) of these were 
male. Other demographic features of these cases classified by 
Table 1  GBA variants found in the 1893 recently diagnosed patients 
from the Tracking Parkinson’s study
Cases,
n (%)
recognised 
Gd pathogenic 
mutations
Pd-associated 
non-Gd 
variants
rare variants of unknown 
significance
30 (1.6%) p.L444P
11 (0.6%) p.N370S
5 (0.3%) p.R463C
2 (0.1%) p.G202R
2 (0.1%) p.R359S
86 (4.5%) p.E326K
35 (1.8%) p.T369M
26* (1.4%) p.D409H, p.F213I,p.G189V,
p.G377S,p.K157Q,
p.L383Xfs,
p.L66P,p.M123T,
p.N382Xfs, p.R163s,
p.R257Q,p.S173s,
p.E481Xfs, p.G10S,
p.G325W,p.R170H,
p.T323I,p.L175I,
p.L324V,p.P55S,
p.R262H,p.R329H
p.R395C,p.T267I,
p.L268L, Asp315His,
Exon 3 hemizygous deletion
7† (0.4%) p.A456P, p.V460V
6‡(0.3%) p.D140H, p.I308T,
Ex4 hemizygous deletion
*Each of the 27 variants was found in single cases from our cohort, although one 
individual had two of these variants (total n=26).
†Each variant was found in six cases from our cohort, although some individuals 
had more than one of these variants (total n=7).
‡Each variant was found in two cases from our cohort (total n=6).
GD,  Gaucher’s disease; PD, Parkinson’s disease. 
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genotype (excluding cases with variants of unknown significance 
and those with unusual presentation) compared with non-car-
riers are detailed in table 2.
Cases who carried GD-causing variants in the GBA gene were 
younger (mean age 62.9, SD 12.3 years) compared with non-car-
riers (mean age 67.6 years, SD 9.2 years) (P<0.001), had an 
earlier age at onset (mean 59.7 years, SD 12.8 years) compared 
with non-carriers (mean 64.4 years, SD 9.7 years) (P=0.002) 
and were at a more advanced Hoehn and Yahr stage compared 
with non-carriers (P=0.02) when adjusted for age and disease 
duration (table 2). This was also reflected in greater medica-
tion requirements at baseline in those with GD-causing variants 
(levodopa-equivalent daily dose (LEDD) 370 mg/day, SD 219 mg/
day) compared with non-carriers (LEDD 292 mg/day, SD 206 mg/
day) (P=0.03). The postural instability gait difficulty (PIGD) 
motor subtype was the most common phenotype in those with 
GD-causing variants compared with those with non-carriers 
(adjusted P=0.04) reflecting more axial involvement and less 
tremor. E326K and T369M carriers when analysed together with 
carriers of GD-causing variants also showed PIGD as the most 
common motor subtype compared with non-carriers (adjusted 
P=0.03). The prevalence of anxiety (adjusted P=0.44), depression 
(adjusted P=0.28) and cognitive impairment (adjusted P=0.84) 
was not different between those with GD-causing variants (and 
those carrying the E326K, T369M variants) and non-carriers.
There was no statistically significant difference in the prev-
alence of RBD symptoms between those with mutations in the 
GBA gene and non-carriers (table 2). However, olfactory loss 
was more prevalent in those carrying GD causing mutations than 
non-carriers (P=0.047).
Table 2 Demographic and clinical features of the Parkinson’s disease (PD) cohort classified by GBA mutation carrier status
Variable
Gd-causing variants (group 
1)
n=44
e326K and T369M 
carriers (group 2)
n=98
non-carriers
(group 3)
n=1584
P value*
Group 1 vs 3
P value*
Group 2 vs 3
P value*
Groups 1 and 2 
vs 3
Age (years) 62.9 (12.3) 66.8 (8.7) 67.6 (9.2) <0.001† 0.50† 0.018†
Age at diagnosis (years) 61.4 (12.3) 65.6 (8.7) 66.2 (9.2) <0.001† 0.50† 0.018†
Duration from diagnosis 
(years)
1.5 (1.1) 1.2 (0.9) 1.3 (0.9) 0.15‡ 0.075‡ 0.49‡
Gender, male (%) 28 (63.6%) 65 (66.3%) 1036 (65.4%) 0.93§ 0.83§ 0.90§
HY stage 
  
  0–1.5 (%)
17 (38.6%) 48 (49.0%) 774 (49.3%) 0.015 0.81 0.14
  2 or 2.5 (%) 21 (47.7%) 47 (48.0%) 704 (44.9%)
  3+ (%) 6 (13.6%) 3 (3.1%) 91 (5.8%)
UPDRS 3 24.2 (13.0) 21.8 (11.5) 22.6 (12.2) 0.26¶ 0.72¶ 0.76¶
LEDD (mg/day) 370 (219) 303 (183) 292 (206) 0.028 0.17 0.020
Education≤12 years (%) 14 (34.1%) 29 (31.2%) 483 (32.5%) 0.47 0.91 0.78
Motor subtype 
  
  TD
12 (30.0%) 38 (41.3%) 688 (47.7%)
  PIGD 20 (50.0%) 41 (44.6%) 566 (39.3%) 0.061 0.14 0.027
Indeterminate 8 (20.0%) 13 (14.1%) 187 (13.0%) 0.057 0.44 0.10
Anxiety (%) 14 (33.3%) 24 (25.3%) 355 (23.5%) 0.35 0.76 0.44
Depression (%) 10 (24.4%) 27 (28.1%) 338 (22.3%) 0.98 0.20 0.28
QOL score 6.2 (4.9) 6.0 (5.0) 5.7 (4.7) 0.91 0.42 0.46
Family history of PD 
  First degree (%) 5 (11.4%) 8 (8.2%) 194 (12.3%) 0.82 0.20 0.24
  Second degree (%) 6 (13.6%) 4 (4.1%) 155 (9.9%) 0.55 0.063 0.23
  Any (%) 9 (20.5%) 12 (12.2%) 319 (20.3%) 0.87 0.048 0.087
Ethnicity 
  
  White
44 (100%) 98 (100%) 1531 (98.0%) NA NA NA
  Asian or Asian British – – 15 (1.0%) – – – 
  Black or black British – – 12 (0.8%) – – – 
  Mixed – – 3 (0.2%) – – – 
  Others – – 2 (0.1%) – – – 
RBD symptoms (%) 17 (43.6%) 46 (49.5%) 638 (43.1%) 0.92 0.20 0.31
Olfactory loss 33 (86.8%) 69 (80.2%) 968 (71.0%) 0.047 0.062 0.009
Data are shown as mean and SD unless expressed otherwise.
*Adjusted for age, gender and disease duration (except where otherwise noted).
†Adjusted for gender and disease duration.
‡Adjusted for gender and age.
§Adjsuted for age and disease duration.
¶Adjusted for age, gender, disease duration and LEDD.
GD, Gaucher’s disease; HY, Hoehn and Yahr stage; LEDD, levodopa-equivalent daily dose;  NA, not available; PIGD, postural instability gait difficulty; QOL, quality of life based on 
PDQ8 scale; RBD, rapid eye movement sleep behaviour disorder; TD, tremor dominant; UPDRS 3, Movement Disorder Society Unified Parkinson’s Disease Rating Scale part 3.
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Cognitive profiles based on MoCA testing
There was no difference in cognition as measured by average 
MoCA test score or proportion of patients with dementia 
between those with and without pathogenic GBA mutations 
(table 3). There was no difference in cognition between possibly 
atypical PD cases carrying GBA mutations and PD non-carriers. 
(online supplementary table 1). Compared with non-carriers, 
those with GD-causing variants had lower scores on the naming 
domain of the MoCA test when adjusted for age, gender, disease 
duration and years of education (adjusted P=0.01), which did 
not survive correction for multiple testing. There were no signif-
icant group differences between those with GD-causing variants, 
E326K and T369M carriers and non-carriers in the scores of 
other domains of cognitive function such as attention (adjusted 
P=0.18), orientation (adjusted P=0.28), language (adjusted 
P=0.37) and delayed recall (adjusted P=0.67). However, E326K 
and T369M carriers had significant lower scores on the abstrac-
tion domain compared with those carrying GD-causing variants 
(adjusted P=0.02).
Repeating the analyses for motor features, cognitive impair-
ment and behavioural domains did not change the results.
Cases with p.L444P mutations did not show any difference in 
total MoCA test scores or any of the subdomains except naming 
(with a very small absolute difference) with non-carriers (online 
supplementary table 1). Cases with p.L444P mutations did not 
show any difference in any of the subdomains or total MoCA 
test scores compared with p.N370S mutation carriers (online 
supplementary table 2).
The data available from the answers to the six questions from 
part 1 of the MDS-UPDRS scale provide a measure of the impact 
of cognitive dysfunction and complex behaviours on the ability 
to perform activities of daily living as shown in table 4.
Finally, the imputed analyses showed no qualitative differ-
ences between the imputed and complete case results (online 
supplementary tables 1-7).
dIsCussIOn
To our knowledge, this is the largest single cohort study exam-
ining the influence of GBA mutations in newly diagnosed PD 
in terms of age at onset, motor phenotype and cognitive func-
tions. We found that GBA mutations affected age at onset of PD 
and the motor phenotype, with no apparent effect on any aspect 
of cognition at the early stages of the disease process (average 
disease duration 1.5 years). We excluded patients with dementia 
at baseline as this is necessary to define PD as per Queen Square 
Brain Bank criteria.21 This means that patients with GBA-associ-
ated DLB are not included in this study.
2.5% of our cohort carried one or more pathogenic mutations 
in the GBA gene. This is lower than the proportion of cases found 
in a meta-analysis of European studies (5.5%)26 and a North Amer-
ican study (4.4%)18 but closer to the rate of GBA mutations found 
in a meta-analysis of data from studies in the Chinese population 
(3.6%).27 Higher proportions in other studies probably reflect 
data from enriched populations due to a referral bias to specialist 
centres for genetic testing. Our study reflects data collected from 
the National Health Service hospitals that normally provide routine 
healthcare in the UK, reflecting a diverse unbiased population pool 
in the community. L444P was the most common pathogenic GBA 
mutation (1.6%) in patients with PD in our study. This is in keeping 
with the results of a previous study from China that showed L444P 
as the most common mutation detected in GBA in cases with PD 
(n=402).27 This is not surprising given that L444P is a common 
pan-ethnic mutation while N370S is the most common mutation in 
Jewish populations.4
Some have suggested that GBA mutation carriers are more 
likely to have a family history of PD28 but we did not find any 
significant differences in the proportion of people with or without 
GBA mutations and a family history of PD among first-degree or 
second-degree relatives. We did not directly ask our participants 
whether they had Jewish ancestry but <1% reported that their 
religion was Judaism even though we included study centres in 
UK populations with large Jewish communities: North London, 
Manchester and Glasgow.
We found E326K in 4.5% of our patients with PD, which 
is close to the 4.7% figure reported in a cohort of similar size 
(n=1369) from the USA.18 The background control frequency of 
E326K in the UK has been reported to be approximately 2.5%. 
In our series, E326K was not associated with early-onset PD. 
One case in our series was homozygous for the E326K variant 
and had an age of onset 64.6 years and had similar motor 
features to E326K and T369M heterozygote carriers (group 2). 
This homozygous E326K case did not have GD, confirming that 
Table 4 Cognitive and behavioural impairment in the GBA-associated Parkinson’s disease cohort based on the Movement Disorder Society Unified 
Parkinson’s disease rating scale part 1 scores dichotomised at 1 or above
Variable
Gd-causing 
variants 
(group 1)
n=44
e326K and 
T369M 
carriers 
(group 2)
n=98
non-carriers
(group 3)
n=1584
Or*
(95% CI)
Group 1 vs 3
P value*
Group 1 
vs 3
Or*
(95% CI)
Group 2 vs 3
P value*
Group 2 
vs 3
Or*
(95% CI)
Groups 1 and 2 vs 3
P value*
Groups 1 
and 2 vs 3
Cognitive 
impairment
16 (36.4%) 36 (36.7%) 620 (39.6%) 0.96 (0.51 to 1.81) 0.89 0.93 (0.61 to 1.43) 0.74 0.94 (0.65 to 1.35) 0.73
Hallucinations 
and psychosis
6 (13.6%) 8 (8.2%) 137 (8.8%) 1.70 (0.70 to 4.13) 0.24 1.00 (0.47 to 2.11) 1 1.21 (0.68 to 2.17) 0.52
Depressed 
mood
17 (38.6%) 35 (35.7%) 574 (36.6%) 1.01 (0.54 to 1.87) 0.98 0.95 (0.62 to 1.46) 0.83 0.97 (0.68 to 1.39) 0.87
Anxious mood 22 (50.0%) 46 (46.9%) 769 (49.1%) 0.95 (0.52 to 1.75) 0.88 0.90 (0.60 to 1.37) 0.63 0.92 (0.65 to 1.30) 0.63
Apathy 13 (29.5%) 38 (38.8%) 464 (29.7%) 0.94 (0.48 to 1.82) 0.85 1.48 (0.97 to 2.26) 0.069 1.29 (0.90 to 1.86) 0.16
Impulse 
control 
disorders
2 (4.5%) 9 (9.4%) 82 (5.2%) 0.66 (0.15 to 2.83) 0.58 1.96 (0.95 to 4.06) 0.070 1.46 (0.75 to 2.83) 0.26
Data are presented in the table as n (%).
* Adjusted for age, gender and disease duration. 
GD, Gaucher’s disease.
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homozygosity for this allele does not cause GD, as described 
by others.7 One recent study reported the frequency of the 
E326K polymorphism in their cohort of patients with PD was 
no different from their controls , suggesting that E326K was not 
pathogenic for PD.29 However, results from a meta-analysis of 
data from five recent PD genome-wide association studies indi-
cated that E326K is a susceptibility allele for PD.30
We found that our cases with GBA mutations were younger 
at diagnosis compared with non-carriers by about 5 years. 
Our data are consistent with a study from North America that 
reported similar findings.31 Another study from Germany simi-
larly showed the age of onset in GBA mutation carriers was 
on average 6 years earlier compared with non-carriers,12 and a 
previous meta-analysis of several studies showed GBA mutation 
carriers had an earlier age of onset of around 4.6 years compared 
with PD patients without GBA mutations.32
We confirm previous reports suggesting that GBA variants 
can influence the motor phenotype of patients with PD.32 Those 
with GBA mutations in our study were at a more advanced 
Hoehn and Yahr stage, even when adjusted for disease duration, 
compared with non-carriers, which is consistent with previous 
reports.11 However, the UPDRS motor scores in our study were 
not significantly different between the groups, although all our 
patients were assessed ‘on’ medication. Those with GBA muta-
tions (including E326K and T369M) were more likely to have 
the PIGD phenotype compared with non-carriers and had higher 
dopaminergic therapy requirements compared with non-car-
riers, possibly explaining the lack of difference in UPDRS motor 
scores. This was not reported by Winder-Rhodes et al in their 
mutation carriers (n=9),11 possibly because differences can be 
difficult to detect with small numbers of patients.
Earlier reports found that GBA variants are associated with 
greater impairment in working memory, executive function and 
visuospatial abilities18 and GBA mutations confer a greater risk 
of dementia during the course of PD.17
The development of therapeutic agents that exploit the key 
pathological pathways in GBA-associated PD include the small 
molecular chaperone Ambroxol,33 which crosses the blood–
brain barrier when administered orally, have been shown to 
increase GBA enzyme activity in primate models.34 Therefore, if 
such therapeutic strategies were to become available for humans, 
we would need to identify a window of opportunity before the 
onset of dementia in GBA-associated PD where such interven-
tions would have the maximum impact. Those earlier studies 
were reporting differences in cognitive function at an average 
disease duration of 12–15 years,16 17 whereas we are presenting 
baseline data.
Our findings are consistent with other previous studies that 
describe patients at this relatively early stage of the disease 
course (<3.5 years from disease onset) in which they did not 
find differences in cognitive function between patients carrying 
GBA mutations and non-carriers.9 11 35 Importantly, in those 
studies where cognitive scores were assessed longitudinally, 
patients carrying GBA mutations only begin to show divergence 
in cognitive performance around 36 months after motor onset 
(or diagnosis).9 11
The cognitive measures used in our study are restricted to the 
MoCA test. It is a widely validated test with sensitivity to detect 
changes in several cognitive domains for screening all levels of 
cognition in PD.23 Sensitivity and specificity for PD dementia 
using MoCA are 81%–82% and 75%–95%, respectively. 
Sensitivity and specificity for MCI in PD are 83%–90% and 
53%–75%, respectively.23 We did not detect any differences at 
early-stage disease between those with pathogenic mutations in 
GBA and non-carriers in the attention, orientation, language, 
delayed recall and visuospatial domains using the MoCA test. 
While the MoCA has good sensitivity for detecting dementia 
and is a test of global cognition, subtle differences in individual 
cognitive domains may not be detected using the MoCA test 
even where they exist. Future studies could specifically address 
this issue with more sensitive neuropsychological measures in 
patients with specific mutations in order to detect more subtle 
cognitive deficits that may be found at an earlier stage.
Previous reports from genotype–phenotype correlative studies 
have suggested that those with p.L444P mutations (which are 
thought to cause a more severe GD phenotype) have a greater 
degree of cognitive impairment compared with patients with 
p.N370S mutations (which are thought to cause a less severe GD 
phenotype).8 We did not detect any differences in the cognitive 
performance on the MoCA test at this early stage in the disease 
in patients with these 2 types of mutations.
Besides cognitive impairment, previous reports suggest 
more severe anxiety and depression in GBA-associated PD 
compared with those with sporadic PD.35 36 The prevalence of 
anxiety in our study was not significantly different in patho-
genic GD mutation carriers compared with non-carriers, and 
the same was true for depression Furthermore, we did not find 
any significant differences between the prevalence of neurobe-
havioural and psychiatric symptoms such as psychosis between 
the three groups of patients in our study. This may relate to the 
relatively early stage of disease in our cohort with a relatively 
shorter disease duration as psychosis in PD typically occurs in 
the later stages of the disease and after several years of treat-
ment37 38 and differences may emerge with longer follow-up 
duration.
Strengths of our study include comprehensive screening of the 
GBA gene as opposed to selective mutation detection; the size of 
the study and the representative population base. Weaknesses of 
our paper include the cross-sectional family history data and the 
use of a brief cognitive screening tool.
COnClusIOn
We show that patients with PD and GBA mutations are different 
from GBA mutation non-carriers. GBA mutation carriers had an 
earlier age of onset, more commonly had the PIGD phenotype 
and had more severe motor impairment. In line with previous 
studies, global cognition scores did not differ between GBA 
mutation carriers and non-carriers at early stages in the disease 
process. Follow-up data emerging from this study will be used 
to reassess cognitive function in GBA mutation carriers at a later 
stageas well as the development of any neuropsychiatric and 
behavioural problems.
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